SCHEMBL4238085

SCHEMBL4238085

CCc1c(F)cccc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALB P02768 1/20 0.55
CES2 O00748 3/20 0.44
CES1 P23141 3/20 0.44
BCHE P06276 1/20 0.44
CLCN2 P51788 1/20 0.44
ALDH1A1 P00352 4/20 0.43
ALOX15 P16050 2/20 0.43
MRGPRX4 Q96LA9 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTPN1 P18031 1/20 0.41
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355391 0.86 ALDH1A1 (0.52) ALBCLCN2ALDH1A1ALOX15MRGPRX4
SCHEMBL16429101 0.84 ALB (0.59) ALBCES2CES1BCHEALDH1A1
SCHEMBL17858663 0.83 CES2 (0.42) ALBCES2CES1BCHEALDH1A1
SCHEMBL19695740 0.83 MAPK8 (0.47) ALBCES2CES1BCHEALDH1A1
SCHEMBL30499962 0.83 MAPK8 (0.47) ALBCES2CES1BCHEALDH1A1
SCHEMBL3656083 0.82 ALB (0.57) ALBCES2CES1BCHEALDH1A1
SCHEMBL578127 0.82 CLCN2 (0.56) CLCN2ALDH1A1ALOX15MRGPRX4KDM4E
SCHEMBL10676132 0.81 ALB (0.55) ALBCES2CES1BCHEALDH1A1
SCHEMBL24603694 0.80 GAA (0.62) CES2CES1BCHEALDH1A1KDM4E
SCHEMBL16892196 0.80 ALB (0.50) ALBCES2CES1BCHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4116298-A1 PIPERIDINEDIONE DERIVATIVE Innocure Therapeutics, Inc. (KR) 2023-01-11 EP disclosed
EP-3233839-B1 HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-09-25 EP disclosed
EP-3233862-B1 IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-07-03 EP disclosed
US-10202387-B2 Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-02-12 US disclosed
US-20180057496-A1 HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS JANSSEN-CILAG (FR) 2018-03-01 US disclosed
US-20180057496-A1 HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS JANSSEN-CILAG (FR) 2018-03-01 US disclosed
US-20180002336-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-01-04 US disclosed
WO-2016097347-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-06-23 WO disclosed
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 US disclosed
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
CN-1129578-C Tetrahydrobenzindole derivatives MEIJI SEIKA KAISHA (JP) 2003-12-03 CN disclosed
CN-1286683-A Tetrahydrobenzindole derivatives MEIJI SEIKA KAISHA (JP) 2001-03-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202387-B2 Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors PIK3CB, PIK3CD, PIK3CA ALB 4823/4885CES2 2099/4885CES1 1394/4885
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R ALB 4332/4885CES2 4081/4885CES1 3769/4885
US-20180002336-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS PIK3CB, PIK3CD, PIK3CA ALB 4613/4885CES2 2147/4885CES1 1384/4885
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 ALB 4599/4885CES2 3273/4885CES1 1348/4885
US-20180057496-A1 HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS PIK3CB, PIK3CD, PIK3CA ALB 4823/4885CES2 2099/4885CES1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.